Janus Global Life Sciences Fund Class C (JFNCX)

58.24
Net Asset Value
-0.90%
1 Day
+17.18%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.80%
Expense Ratio
Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Performance

1 month-1.12% 3 years+38.55%
3 months+5.28% 5 years+30.09%
1 year+47.57% Since inception+26.35%
Data through --

Peer Comparisonvs. Health

 JFNCXCategory
Performance 5-yr return+30.09%+22.35%
Expense ratio1.80%1.42%
Risk 5 year sharpe ratio1.761.48
Net assets$4.5B$3.7B
Average market cap$21.0B$35.4B
Average P/E26.224.6
Portfolio turnover52%52%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyJanus
Fund manager & tenureAndrew Acker / 8 Years
Minimal initial investment$2,500.00
Minimum IRA investment--

Holdings

U.S. stock68.83%
International stock25.64%
Fixed income3.48%
Cash2.06%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 94.74%
Consumer service 3.23%
Consumer goods 0.79%
Business service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
JNJ Johnson & Johnson2.98%
AMGN Amgen2.82%
BIIB Biogen2.71%
ACT Actavis2.41%
-- 2.37%
ABBV AbbVie2.22%
-- 2.15%
CELG Celgene2.15%
BSX Boston Scientific Corp1.96%
-- 1.89%

To view my watchlist

Not a member yet?

Sign up now for a free account